ID   CWR-R1-I567
AC   CVCL_ZC62
SY   R1-I567
DR   cancercelllines; CVCL_ZC62
DR   Kerafast; EMN029-FP
DR   Wikidata; Q98125807
RX   PubMed=24101480;
CC   Population: Caucasian.
CC   Characteristics: Using TALEN AR introns 4-7 were inverted. This cell line exclusively expresses the ARv567es isoform that skips exons 5 to 7 (PubMed=24101480).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_ZC60 ! CWR-R1-AD1
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=24101480; DOI=10.1073/pnas.1308587110;
RA   Nyquist M.D., Li Y.-M., Hwang T.H., Manlove L.S., Vessella R.L.,
RA   Silverstein K.A.T., Voytas D.F., Dehm S.M.;
RT   "TALEN-engineered AR gene rearrangements reveal endocrine uncoupling
RT   of androgen receptor in prostate cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:17492-17497(2013).
//